 Cleave Therapeutics Inc has out-licensed CB-5339 to CASI Pharmaceuticals Inc NASDAQ: CASI in mainland China, Taiwan, Hong Kong, and Macau. Cleave and CASI will develop CB-5339 in both hematological malignancies and solid tumors under the terms of the agreement, with CASI responsible for development and commercialization in China and associated markets. 